These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 23692521)

  • 1. Modeling phospholipidosis induction: reliability and warnings.
    Goracci L; Ceccarelli M; Bonelli D; Cruciani G
    J Chem Inf Model; 2013 Jun; 53(6):1436-46. PubMed ID: 23692521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting in vivo phospholipidosis-inducing potential of drugs by a combined high content screening and in silico modelling approach.
    Bauch C; Bevan S; Woodhouse H; Dilworth C; Walker P
    Toxicol In Vitro; 2015 Apr; 29(3):621-30. PubMed ID: 25668432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of drugs inducing phospholipidosis by novel in vitro data.
    Muehlbacher M; Tripal P; Roas F; Kornhuber J
    ChemMedChem; 2012 Nov; 7(11):1925-34. PubMed ID: 22945602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How does the quality of phospholipidosis data influence the predictivity of structural alerts?
    Przybylak KR; Alzahrani AR; Cronin MT
    J Chem Inf Model; 2014 Aug; 54(8):2224-32. PubMed ID: 25062434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds.
    Hanumegowda UM; Wenke G; Regueiro-Ren A; Yordanova R; Corradi JP; Adams SP
    Chem Res Toxicol; 2010 Apr; 23(4):749-55. PubMed ID: 20356072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells.
    Atienzar F; Gerets H; Dufrane S; Tilmant K; Cornet M; Dhalluin S; Ruty B; Rose G; Canning M
    Toxicol Sci; 2007 Mar; 96(1):101-14. PubMed ID: 17175557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
    Fischer H; Atzpodien EA; Csato M; Doessegger L; Lenz B; Schmitt G; Singer T
    J Med Chem; 2012 Jan; 55(1):126-39. PubMed ID: 22122484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. pH-gradient PAMPA-based in vitro model assay for drug-induced phospholipidosis in early stage of drug discovery.
    Balogh GT; Müller J; Könczöl A
    Eur J Pharm Sci; 2013 Apr; 49(1):81-9. PubMed ID: 23439241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies.
    Nioi P; Perry BK; Wang EJ; Gu YZ; Snyder RD
    Toxicol Sci; 2007 Sep; 99(1):162-73. PubMed ID: 17567588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposome electrokinetic chromatography based in vitro model for early screening of the drug-induced phospholipidosis risk.
    Wang T; Feng Y; Jin X; Fan X; Crommen J; Jiang Z
    J Pharm Biomed Anal; 2014 Aug; 96():263-71. PubMed ID: 24814828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the phospholipidogenic potential of 4(1H)-pyridone antimalarial derivatives.
    Almela MJ; Torres PA; Lozano S; Herreros E
    Toxicol In Vitro; 2009 Dec; 23(8):1528-34. PubMed ID: 19540329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for the drug-phospholipid interaction: correlation to phospholipidosis.
    Alakoskela JM; Vitovic P; Kinnunen PK
    ChemMedChem; 2009 Aug; 4(8):1224-51. PubMed ID: 19551800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction and Consensus Performance of (Q)SAR Models for Predicting Phospholipidosis Using a Dataset of 743 Compounds.
    Orogo AM; Choi SS; Minnier BL; Kruhlak NL
    Mol Inform; 2012 Oct; 31(10):725-39. PubMed ID: 27476455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromatography approaches for early screening of the phospholipidosis-inducing potential of pharmaceuticals.
    Jiang Z; Reilly J
    J Pharm Biomed Anal; 2012 Mar; 61():184-90. PubMed ID: 22200505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting myelosuppression of drugs from in silico models.
    Crivori P; Pennella G; Magistrelli M; Grossi P; Giusti AM
    J Chem Inf Model; 2011 Feb; 51(2):434-45. PubMed ID: 21275392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A strategy for risk management of drug-induced phospholipidosis.
    Chatman LA; Morton D; Johnson TO; Anway SD
    Toxicol Pathol; 2009 Dec; 37(7):997-1005. PubMed ID: 20008549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High content screening analysis of phospholipidosis: validation of a 96-well assay with CHO-K1 and HepG2 cells for the prediction of in vivo based phospholipidosis.
    van de Water FM; Havinga J; Ravesloot WT; Horbach GJ; Schoonen WG
    Toxicol In Vitro; 2011 Dec; 25(8):1870-82. PubMed ID: 21651975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between in vitro phospholipidosis assay using HepG2 cells and 2-week toxicity studies in rats.
    Miyamoto S; Matsumoto A; Mori I; Horinouchi A
    Toxicol Mech Methods; 2009 Oct; 19(8):477-85. PubMed ID: 19793005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro assays and biomarkers for drug-induced phospholipidosis.
    Monteith DK; Morgan RE; Halstead B
    Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):687-96. PubMed ID: 17014389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting the Risk of Phospholipidosis with in Silico Models and an Image-Based in Vitro Screen.
    Fusani L; Brown M; Chen H; Ahlberg E; Noeske T
    Mol Pharm; 2017 Dec; 14(12):4346-4352. PubMed ID: 29077420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.